株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

加齢性黄斑変性症(AMD)治療薬の世界市場:2019年~2023年

Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 886883
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.77円で換算しております。
加齢性黄斑変性症(AMD)治療薬の世界市場:2019年~2023年 Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023
出版日: 2019年06月28日 ページ情報: 英文 125 Pages
概要

加齢性黄斑変性症(AMD)の罹患率は、この症状を発症する高リスク因子のために、極めて高くなっています。加齢、喫煙、高コレステロール血症、高血圧などの危険因子がAMD発症の主な要因です。しかし、AMDの高い罹患率にもかかわらず、利用可能な承認された治療法が市場にはありません。このように、高い有病率と相まって、ドライ型AMDのアンメット医療ニーズによって、世界の加齢性黄斑変性症(AMD)治療薬市場が予測期間中に8%以上のCAGRで成長が牽引されると予想されます。

当レポートでは、世界の加齢性黄斑変性症(AMD)治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別
  • タイプ別比較:市場規模および予測(2018年~2023年)
  • ウェット型AMD
  • ドライ型AMD
  • 市場機会:タイプ別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 戦略的提携
  • AMDのための遺伝子治療の開発
  • AMDについての意識の高まり

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

図表
  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Type - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by type
  • Exhibit 19: Wet AMD - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Wet AMD - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Dry AMD - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Phase III drugs for dry AMD
  • Exhibit 23: Cell therapies under development for dry AMD
  • Exhibit 24: Dry AMD - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by type
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Population aged 65 years and above (% of total) in Asia 2017
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Some late-stage drugs for treatment of AMD
  • Exhibit 45: Global growth in geriatric population 2013-2017 (%)
  • Exhibit 46: Approximate cost of AMD drugs
  • Exhibit 47: Companies developing biosimilars: Overview
  • Exhibit 48: Side effects associated with drugs used for AMD
  • Exhibit 49: Impact of drivers and challenges
  • Exhibit 50: Vendor landscape
  • Exhibit 51: Landscape disruption
  • Exhibit 52: Vendors covered
  • Exhibit 53: Vendor classification
  • Exhibit 54: Market positioning of vendors
  • Exhibit 55: Amgen Inc. - Vendor overview
  • Exhibit 56: Amgen Inc. - Business segments
  • Exhibit 57: Amgen Inc. - Organizational developments
  • Exhibit 58: Amgen Inc. - Geographic focus
  • Exhibit 59: Amgen Inc. - Key offerings
  • Exhibit 60: Amgen Inc. - Key customers
  • Exhibit 61: Bausch Health Companies Inc. - Vendor overview
  • Exhibit 62: Bausch Health Companies Inc. - Business segments
  • Exhibit 63: Bausch Health Companies Inc. - Organizational developments
  • Exhibit 64: Bausch Health Companies Inc. - Geographic focus
  • Exhibit 65: Bausch Health Companies Inc. - Segment focus
  • Exhibit 66: Bausch Health Companies Inc. - Key offerings
  • Exhibit 67: Bausch Health Companies Inc. - Key customers
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 75: Novartis AG - Vendor overview
  • Exhibit 76: Novartis AG - Business segments
  • Exhibit 77: Novartis AG - Organizational developments
  • Exhibit 78: Novartis AG - Geographic focus
  • Exhibit 79: Novartis AG - Segment focus
  • Exhibit 80: Novartis AG - Key offerings
  • Exhibit 81: Novartis AG - Key customers
  • Exhibit 82: Regeneron Pharmaceuticals Inc. - Vendor overview
  • Exhibit 83: Regeneron Pharmaceuticals Inc. - Business segments
  • Exhibit 84: Regeneron Pharmaceuticals Inc. - Organizational developments
  • Exhibit 85: Regeneron Pharmaceuticals Inc. - Geographic focus
  • Exhibit 86: Regeneron Pharmaceuticals Inc. - Key offerings
  • Exhibit 87: Regeneron Pharmaceuticals Inc. - Key customers
  • Exhibit 88: Validation techniques employed for market sizing
  • Exhibit 89: Definition of market positioning of vendors
目次
Product Code: IRTNTR31580

About this market

Age-related macular degeneration (AMD) is a bilateral ocular disease that affects the central area of the retina known as the macula. Technavio's age-related macular degeneration considers sales from both wet AMD, dry AMD. Our analysis also considers the sales of AMD in Asia, Europe, North America and ROW. In 2018, the wet AMD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing use of VEGF inhibitors, which are used for the treatment of wet AMD will play a significant role in the wet AMD segment to maintain its market position. Also, our global age-related macular degeneration market report also looks at factors such as high prevalence of AMD, strong pipeline and expected approvals, and rising geriatric populations. However, lack of approved therapies for dry AMD, introduction of biosimilars, side effects of available therapeutics may hamper the growth of the age-related macular degeneration industry over the forecast period.

Overview

High prevalence of AMD

The prevalence of AMD is extremely high, owing to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period.

Development of gene therapy for AMD

There is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.

For the detailed list of factors that will drive the global age-related macular degeneration (and) therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of few major players, the global age-related macular degeneration (AMD) therapeutics market is moderately concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading age-related macular degeneration manufacturers, that include Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.

Also, the age-related macular degeneration market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Wet AMD - Market size and forecast 2018-2023
  • Dry AMD - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Strategic alliances
  • Development of gene therapy for AMD
  • Growing awareness about AMD

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO